Weight LossFDA-approved18 providers

Tesamorelin Therapy: Complete Guide

Tesamorelin (brand name Egrifta) is a growth hormone-releasing hormone (GHRH) analog FDA-approved for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. It stimulates the pituitary gland to produce natural growth hormone, which in turn promotes fat metabolism. It is increasingly used off-label for general visceral fat reduction and anti-aging purposes.

Typical cost: $300 - $600/month

Written by

Megan Williams

Editor-in-Chief

Reviewed by

Brian Williams

Co-founder & Research Editor

Last updated

May 26, 2026

What is Tesamorelin?

What Is Tesamorelin?

Tesamorelin (tesamorelin acetate) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid modification at the N-terminus. It is marketed as Egrifta and is FDA-approved for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients with lipohypertrophy.

Tesamorelin is notable as one of the few FDA-approved GHRH analogs available in the United States, giving it a significant regulatory advantage over other growth hormone-stimulating peptides. Its FDA-approved status provides a level of safety and efficacy validation that most other peptide therapies lack.

Clinical Significance

Tesamorelin was developed by Theratechnologies Inc. and received FDA approval in November 2010. It specifically targets visceral adipose tissue (VAT) — the metabolically active fat that accumulates around internal organs and is strongly associated with cardiovascular disease, insulin resistance, and metabolic syndrome.

Clinical Applications

HIV-associated lipodystrophy: FDA-approved indication for reducing excess abdominal visceral fat
Visceral fat reduction: Off-label use for metabolic syndrome-associated visceral adiposity
NAFLD/MASH: Clinical trials have demonstrated significant liver fat reduction
Growth hormone optimization: As an FDA-approved GHRH analog for GH-related benefits
Body composition: Improving the ratio of visceral fat to lean mass
Cognitive function: Emerging research on GH-mediated cognitive benefits

Tesamorelin is available by prescription and through compounding pharmacies. Its FDA approval and clinical trial evidence base make it one of the most well-validated peptide therapies in the growth hormone optimization category.

How Tesamorelin Works

GHRH Receptor Agonism

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural production and release of endogenous growth hormone. As a full-length GHRH analog (all 44 amino acids), it provides complete receptor activation.

The trans-3-Hexenoic Acid Modification

The key structural innovation is the addition of trans-3-hexenoic acid to the tyrosine at position 1. This modification:

Protects against enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV)
Extends the biological half-life compared to native GHRH
Maintains full receptor binding affinity and signaling potency

Visceral Fat Targeting

The GH released by tesamorelin has preferential effects on visceral adipose tissue:

GH activates hormone-sensitive lipase in visceral fat cells, promoting lipolysis
Visceral adipocytes have higher GH receptor density than subcutaneous fat cells, making them more responsive to GH
GH reduces lipogenesis (new fat formation) in visceral depots
The IGF-1 produced downstream further supports lipid metabolism

Physiological GH Pattern

Like other GHRH analogs, tesamorelin preserves the pulsatile pattern of GH release and maintains somatostatin-mediated negative feedback. This provides a more physiological GH profile compared to exogenous GH injection.

Benefits & Uses

FDA-Validated Benefits of Tesamorelin

As an FDA-approved therapy, tesamorelin's benefits have been rigorously demonstrated in randomized controlled trials:

Visceral fat reduction: The pivotal clinical trials demonstrated an average 15–18% reduction in visceral adipose tissue at 26 weeks, measured by CT scan. This is clinically meaningful given that visceral fat is the most metabolically dangerous fat depot (Falutz et al., JAMA, 2007).
Trunk fat reduction: Significant reductions in trunk fat alongside visceral fat reduction, improving overall abdominal body composition.
Liver fat reduction: A study by Stanley et al. (The Lancet HIV, 2014) showed that tesamorelin reduced hepatic fat by approximately 37% in HIV patients with NAFLD, representing a potentially important therapy for liver fat accumulation.
Improved lipid profiles: Reductions in triglycerides and improvements in cholesterol ratios observed in clinical trials.
Preserved or improved lean mass: Unlike simple caloric restriction, tesamorelin-mediated fat loss occurs with preservation of lean body mass.
Improved body image and quality of life: Patient-reported outcomes showed significant improvements in body image, self-esteem, and quality of life measures.
Cognitive benefits: A study by Schwarz et al. (Archives of Neurology, 2008) found that tesamorelin improved cognition in healthy older adults, suggesting GH-mediated neuroprotective effects.
Cardiovascular risk markers: Improvements in inflammatory markers, adiponectin, and other cardiovascular risk biomarkers.

Clinical Evidence & Research

Clinical Trial Evidence

Pivotal FDA approval trials (Falutz et al., JAMA, 2007; Falutz et al., JAIDS, 2008): Two randomized, double-blind, placebo-controlled Phase III trials in HIV patients with lipodystrophy. Tesamorelin 2 mg daily reduced visceral adipose tissue by 15–18% at 26 weeks vs. increases of 5% in placebo groups. Trunk fat and waist circumference also significantly decreased.

Liver fat reduction (Stanley et al., The Lancet HIV, 2014): Randomized trial demonstrating that tesamorelin reduced hepatic fat fraction by approximately 37% in HIV patients with hepatic steatosis, compared to a 10% increase in the placebo group. This led to ongoing investigation of tesamorelin for NAFLD treatment.

Cognitive function (Schwarz et al., Archives of Neurology, 2008): Randomized, double-blind, placebo-controlled trial in healthy older adults (60–90 years). Tesamorelin improved executive function and verbal memory compared to placebo over 20 weeks, with effects correlating with IGF-1 increases.

Long-term safety (Falutz et al., JAIDS, 2010): Extension studies of up to 52 weeks confirmed sustained visceral fat reduction and maintained safety profile. No tachyphylaxis (reduced response) was observed with continued use.

"Tesamorelin is the first and only therapy specifically approved for the reduction of excess abdominal fat in HIV-infected patients, addressing a significant unmet medical need." — FDA approval announcement, 2010

Side Effects & Safety

Side Effect Profile

Tesamorelin's safety profile is well-established through FDA-required clinical trials involving over 800 patients.

Common Side Effects (Mild)

Injection site reactions — Erythema, pruritus, pain, and swelling at the injection site. Reported in approximately 24% of patients; most reactions are mild.
Arthralgia (joint pain) — Reported in approximately 13% of patients; related to GH effects.
Peripheral edema — Mild fluid retention, particularly in extremities, in approximately 6% of patients.
Myalgia (muscle pain) — Reported in approximately 6% of patients.

Less Common Side Effects (Moderate)

Paresthesia — Tingling or numbness, typically in extremities; in approximately 5% of patients.
Pain in extremities — Reported in approximately 5% of patients.
Nausea — Occasionally reported; usually mild.
Rash — Uncommon; typically mild and self-limited.

Monitoring Considerations

IGF-1 levels: Should be monitored periodically; treatment should be reassessed if IGF-1 exceeds the upper limit of normal.
Glucose metabolism: While tesamorelin does not significantly impair glucose tolerance, periodic monitoring of fasting glucose and HbA1c is recommended.
Hypersensitivity: Rare allergic reactions have been reported; discontinue if significant hypersensitivity occurs.

The overall safety profile supports long-term use, with clinical trial data available for up to 52 weeks of continuous treatment.

Dosing & Administration

FDA-Approved Dosing

Dose: 2 mg subcutaneously once daily
Timing: Administered at the same time each day; can be given at any time
Duration: Continuous daily use; effects reverse upon discontinuation

Off-Label Dosing Protocols

Anti-aging / body composition: 1–2 mg subcutaneously daily
Alternate-day dosing: Some practitioners use 2 mg every other day for maintenance

Administration: Subcutaneous injection in the abdominal area. The Egrifta product comes as a lyophilized powder that is reconstituted with provided sterile water. Rotate injection sites to minimize injection site reactions.

Monitoring: Baseline and periodic IGF-1 levels are recommended. If IGF-1 exceeds 3 standard deviations above the age-adjusted mean, the dose should be reduced or treatment discontinued.

Clinical note: The effects of tesamorelin on visceral fat are reversible; visceral fat returns toward baseline upon discontinuation. This necessitates ongoing treatment or transition to other metabolic interventions for sustained benefit. Unlike GLP-1 agonists, tesamorelin does not require dose escalation.

See the full Tesamorelin dosage chart — reconstitution, units, and use-case protocols

Find Tesamorelin Providers Near You

Browse 18 verified providers offering Tesamorelin therapy in our directory. Compare clinics by location, telehealth availability, insurance acceptance, and patient reviews.

Browse Providers

Tesamorelin FAQ

Yes, tesamorelin (brand name Egrifta) is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is used off-label for other indications including visceral fat reduction, anti-aging, and cognitive support.

Tesamorelin is the only FDA-approved GHRH analog in the US, giving it the strongest regulatory and safety validation. It contains all 44 amino acids of native GHRH (vs. 29 for sermorelin) and has been studied in multiple randomized controlled trials. It specifically targets visceral fat reduction, which is well-documented in its clinical trial data.

Clinical trial data shows tesamorelin reduced liver fat by approximately 37% in HIV patients with NAFLD. This has generated significant interest in tesamorelin for liver fat reduction in the general population. While the FDA approval is specific to HIV-associated lipodystrophy, many clinicians use it off-label for liver fat concerns.

In clinical trials, tesamorelin was not associated with clinically significant changes in glucose tolerance or HbA1c. However, growth hormone can affect insulin sensitivity, so periodic monitoring of glucose parameters is recommended, particularly in patients with diabetes risk factors.

Yes, the visceral fat-reducing effects of tesamorelin are reversible. Clinical trial data showed that visceral fat returned toward baseline levels after treatment discontinuation. Ongoing treatment or transition to other metabolic interventions is needed to maintain benefits.

While the FDA approval is specific to HIV-associated lipodystrophy, tesamorelin is widely used off-label in non-HIV patients for visceral fat reduction, body composition optimization, and anti-aging purposes. The clinical trial data in HIV patients provides safety and efficacy evidence that clinicians apply to broader patient populations.